var data={"title":"Disorders of ventilatory control","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Disorders of ventilatory control</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/contributors\" class=\"contributor contributor_credentials\">Douglas C Johnson, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/contributors\" class=\"contributor contributor_credentials\">Scott Manaker, MD, PhD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/contributors\" class=\"contributor contributor_credentials\">Helen Hollingsworth, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/contributors\" class=\"contributor contributor_credentials\">April F Eichler, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jul 27, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The respiratory system is dependent upon a complex system of ventilatory control to ensure appropriate and adequate ventilation in order to supply oxygen, remove carbon dioxide, and maintain acid-base homeostasis. Respiratory centers in the brain integrate input from neural and chemical receptors and provide neuronal drive to the respiratory muscles, which maintain upper airway patency and drive the thoracic bellows to determine the level of ventilation.</p><p>The abnormalities of ventilatory control that result from a variety of disorders, including chronic obstructive pulmonary disease (COPD), asthma, Ondine's curse, carotid body resection, Cheyne-Stokes respiration, myxedema, starvation, and neuromuscular disease, will be reviewed here. In addition, the effects of several pharmacologic agents on ventilation and ventilatory control will be reviewed. The physiologic aspects of ventilatory control and the evaluation of patients with disorders of ventilation are discussed separately. (See <a href=\"topic.htm?path=control-of-ventilation\" class=\"medical medical_review\">&quot;Control of ventilation&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">CHRONIC OBSTRUCTIVE PULMONARY DISEASE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Development of hypercapnia in patients with chronic obstructive pulmonary disease (COPD) generally is associated with more severe disease, but is inconsistent among patients with similar degrees of airflow obstruction. Thus, patients with similar spirometric values can exhibit the &quot;blue bloater&quot; profile of hypercapnia (CO<sub>2</sub> retention, with an elevated arterial carbon dioxide tension [PaCO<sub>2</sub>]) and hypoxemia or the &quot;pink puffer&quot; profile with eucapnia and relatively normal oxygen levels [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/1,2\" class=\"abstract_t\">1,2</a>]. Those in the first group have reduced respiratory drive whereas the latter have increased drive.</p><p>The pattern of breathing in patients with chronic CO<sub>2</sub> retention is characterized by a low tidal volume and high frequency, usually &ge;22 <span class=\"nowrap\">breaths/minute</span>. This respiratory pattern in combination with impaired matching of ventilation and perfusion leads to increased dead space ventilation and diminished alveolar ventilation, which contributes to CO<sub>2</sub> retention [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/3\" class=\"abstract_t\">3</a>].</p><p>Some hypercapnic, hypoxemic patients with COPD develop increased CO<sub>2</sub> retention when O<sub>2</sub> is administered. Such patients usually have both blunted hypercapnic and hypoxic drives [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/4\" class=\"abstract_t\">4</a>]. Other factors contributing to CO<sub>2</sub> retention during O<sub>2</sub> breathing include worsening of ventilation-perfusion distribution secondary to relief of compensatory pulmonary vasoconstriction [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/5\" class=\"abstract_t\">5</a>], and unloading of CO<sub>2</sub> due to the Haldane effect [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/6\" class=\"abstract_t\">6</a>]. (See <a href=\"topic.htm?path=the-evaluation-diagnosis-and-treatment-of-the-adult-patient-with-acute-hypercapnic-respiratory-failure\" class=\"medical medical_review\">&quot;The evaluation, diagnosis, and treatment of the adult patient with acute hypercapnic respiratory failure&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">ASTHMA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In some patients with asthma, an increased risk of near fatal asthma exacerbations, characterized by severe hypoxemia and hypercapnia, is associated with a depressed ventilatory drive. Even during periods of disease quiescence when patients have no bronchospasm, patients with a history of near fatal asthma demonstrate depressed hypoxic and hypercapnic ventilatory responses as well as a reduced perception of dyspnea with added resistive loads (<a href=\"image.htm?imageKey=PULM%2F61737\" class=\"graphic graphic_figure graphicRef61737 \">figure 1</a> and <a href=\"image.htm?imageKey=PULM%2F62712\" class=\"graphic graphic_figure graphicRef62712 \">figure 2</a>)&nbsp;[<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/7\" class=\"abstract_t\">7</a>]. (See <a href=\"topic.htm?path=identifying-patients-at-risk-for-fatal-asthma\" class=\"medical medical_review\">&quot;Identifying patients at risk for fatal asthma&quot;</a>.)</p><p>Patients with asthma who have depressed chemosensitivity and inappropriately low sensations of dyspnea probably delay seeking medical treatment during an asthma attack, resulting in their increased risk of fatal asthma. Asthmatic subjects who develop CO<sub>2</sub> retention during an asthma attack are likely to repeat the same in subsequent attacks [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/7-9\" class=\"abstract_t\">7-9</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">ONDINE'S CURSE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The term Ondine's curse has been applied to patients with alveolar hypoventilation due to impaired autonomic control of ventilation, but whose voluntary control remains intact. Classically, they &quot;forget to breathe&quot; when they fall asleep, but maintain relatively normal blood gases while awake [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/10,11\" class=\"abstract_t\">10,11</a>].</p><p>Ondine's curse is usually due to congenital central hypoventilation syndrome, but can also be caused by brainstem tumors and surgical incisions into the second cervical segment of the spinal cord to relieve intractable pain [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/12,13\" class=\"abstract_t\">12,13</a>]. Paroxysmal central apnea has also been observed following medullary infarction [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/14,15\" class=\"abstract_t\">14,15</a>]. (See <a href=\"topic.htm?path=stroke-related-pulmonary-complications-and-abnormal-respiratory-patterns#H15\" class=\"medical medical_review\">&quot;Stroke-related pulmonary complications and abnormal respiratory patterns&quot;, section on 'Apnea'</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Congenital central hypoventilation syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Congenital central hypoventilation syndrome (CCHS) is a rare genetic disorder caused by a defect in the <em>PHOX2B</em> (paired-like homeobox 2B) gene that typically presents with cyanosis occurring primarily during sleep [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/16\" class=\"abstract_t\">16</a>]. CCHS is associated with a nearly absent respiratory response to hypoxia and hypercapnia, no respiratory discomfort during CO<sub>2</sub> inhalation, mildly elevated arterial carbon dioxide tension (PaCO<sub>2</sub>) during wakefulness, and markedly elevated PaCO<sub>2</sub> during non-REM sleep [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/17-20\" class=\"abstract_t\">17-20</a>]. Patients with CCHS increase their ventilation and maintain relatively normal PaCO<sub>2</sub> levels during exercise and lower their PaCO<sub>2</sub> during passive leg cycling due to nonchemoreceptive inputs [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/21-24\" class=\"abstract_t\">21-24</a>].</p><p>The evaluation and management of CCHS and its associations with Hirschsprung's disease and neural crest tumors are described separately. (See <a href=\"topic.htm?path=congenital-central-hypoventilation-syndrome-and-other-causes-of-sleep-related-hypoventilation-in-children#H267786\" class=\"medical medical_review\">&quot;Congenital central hypoventilation syndrome and other causes of sleep-related hypoventilation in children&quot;, section on 'Congenital central hypoventilation syndrome'</a>.) </p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Late-onset central hypoventilation syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Unlike congenital central hypoventilation syndrome (CCHS), which has a neonatal onset, late-onset central hypoventilation syndrome (LO-CHS) can develop anytime from infancy through adulthood. Like CCHS, these late-presenting cases are caused by <em>PHOX2B</em> mutations. The clinical features, diagnosis, and management of LO-CHS are described separately. (See <a href=\"topic.htm?path=congenital-central-hypoventilation-syndrome-and-other-causes-of-sleep-related-hypoventilation-in-children#H267882\" class=\"medical medical_review\">&quot;Congenital central hypoventilation syndrome and other causes of sleep-related hypoventilation in children&quot;, section on 'Late-onset central hypoventilation syndrome (LO-CHS)'</a>.)</p><p class=\"headingAnchor\" id=\"H21873808\"><span class=\"h2\">Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>ROHHAD is associated with rapid-onset obesity and central hypoventilation during sleep starting after 1.5 years of age, and also hypothalamic dysfunction and absence of a CCHS-related <em>PHOX2B</em> mutation (<a href=\"image.htm?imageKey=PEDS%2F88393\" class=\"graphic graphic_table graphicRef88393 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/25-27\" class=\"abstract_t\">25-27</a>]. </p><p>In addition to hypothalamic-pituitary abnormalities, patients develop symptoms of autonomic nervous system dysfunction (hyperthermia or hypothermia). About 40 percent develop neural crest tumors 7 to 16 years after the onset of obesity. At present there is no genetic testing available to diagnose ROHHAD, other than excluding the presence of a <em>PHOX2B </em>mutation. The evaluation and management of ROHHAD are discussed separately. (See <a href=\"topic.htm?path=congenital-central-hypoventilation-syndrome-and-other-causes-of-sleep-related-hypoventilation-in-children#H267888\" class=\"medical medical_review\">&quot;Congenital central hypoventilation syndrome and other causes of sleep-related hypoventilation in children&quot;, section on 'Rapid-onset obesity with hypothalamic dysfunction (ROHHAD)'</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">CAROTID BODY RESECTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Carotid body resection, or glomectomy, was introduced as a treatment for asthma in Japan during the 1940s, and used in the United States until the 1960s, when controlled studies of the procedure did not support its efficacy [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/28\" class=\"abstract_t\">28</a>]. Carotid body resection has been used for relief of dyspnea in patients with severe COPD, leading to improved dyspnea, but worse hypoxemia and hypercapnia [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/29\" class=\"abstract_t\">29</a>]. </p><p>Glomectomy depresses the hypoxic ventilatory response during exercise; minor abnormalities may also be seen in CO<sub>2</sub> regulation during exercise, but eucapnia is generally present at rest [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/30\" class=\"abstract_t\">30</a>]. </p><p>Bilateral endarterectomy for carotid occlusive disease also may result in destruction of peripheral chemoreceptors, with diminution of hypoxic ventilatory response and slight elevation of resting arterial tension of carbon dioxide (PaCO<sub>2</sub>).</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">CHEYNE-STOKES RESPIRATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cheyne-Stokes respiration (CSR) describes cyclic breathing in which apnea is followed by gradually increasing respiratory frequency and tidal volume (ie, hyperpnea), then gradually decreasing respiratory frequency and tidal volume until the next apneic period [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/31\" class=\"abstract_t\">31</a>]. It is considered a type of central sleep apnea syndrome. (See <a href=\"topic.htm?path=sleep-disordered-breathing-in-heart-failure\" class=\"medical medical_review\">&quot;Sleep-disordered breathing in heart failure&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Mechanism</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Delay between changes in ventilation and detection of the resulting arterial tension of carbon dioxide (ie, PaCO<sub>2</sub>) by the central chemoreceptors maintains a cyclic pattern of respiration. Factors believed to contribute to this delay include prolonged lung to brain circulation time, reduced tissue and lung CO<sub>2</sub> and O<sub>2</sub> stores, and increased ventilatory drive. The increased ventilatory drive is due, at least in part, to loss of effective damping factors.</p><p>In contrast to normal physiology, the lowest arterial oxygen saturation and highest PaCO<sub>2</sub> occur near peak hyperpnea in CSR, suggesting that the level of PaCO<sub>2</sub> at any given moment reflects the patient's stimulation to breathe and not the effectiveness of ventilation.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Comorbidities</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cheyne-Stokes respiration is commonly associated with cardiac disease; it can also accompany neurologic disease, sedation, normal sleep, acid-base disturbances, prematurity, and altitude acclimatization [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/32-34\" class=\"abstract_t\">32-34</a>]. In one study of 42 patients with stable heart failure, 45 percent of patients had more than 20 episodes of apneas or hypopneas per hour of sleep [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/35\" class=\"abstract_t\">35</a>]. (See <a href=\"topic.htm?path=sleep-disordered-breathing-in-heart-failure\" class=\"medical medical_review\">&quot;Sleep-disordered breathing in heart failure&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H5551029\"><span class=\"h2\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnostic evaluation of suspected sleep-disordered breathing is the same for patients with or without heart failure. An in-laboratory overnight polysomnogram is the gold standard diagnostic test. (See <a href=\"topic.htm?path=central-sleep-apnea-risk-factors-clinical-presentation-and-diagnosis#H10\" class=\"medical medical_review\">&quot;Central sleep apnea: Risk factors, clinical presentation, and diagnosis&quot;, section on 'Diagnostic evaluation'</a> and <a href=\"topic.htm?path=sleep-disordered-breathing-in-heart-failure#H6\" class=\"medical medical_review\">&quot;Sleep-disordered breathing in heart failure&quot;, section on 'Diagnosis'</a>.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Management</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Management of CSR focuses on treatment of the underlying cause (eg, optimizing medical therapy of heart failure), but may also include continuous positive airway pressure (CPAP) during sleep, supplemental oxygen, or adaptive servoventilation (ASV) in selected patients. The management of CSR is discussed in more detail separately. (See <a href=\"topic.htm?path=sleep-disordered-breathing-in-heart-failure#H8\" class=\"medical medical_review\">&quot;Sleep-disordered breathing in heart failure&quot;, section on 'Management'</a>.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">MYXEDEMA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hypoventilation can occur in patients with severe hypothyroidism [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/36\" class=\"abstract_t\">36</a>]. It probably reflects both respiratory muscle weakness and depression of ventilatory drive [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/37,38\" class=\"abstract_t\">37,38</a>]. Some patients will need noninvasive or invasive ventilatory support during the initial phases of thyroid replacement. The evaluation and management of myxedema are discussed separately. (See <a href=\"topic.htm?path=respiratory-function-in-thyroid-disease\" class=\"medical medical_review\">&quot;Respiratory function in thyroid disease&quot;</a> and <a href=\"topic.htm?path=myxedema-coma\" class=\"medical medical_review\">&quot;Myxedema coma&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h1\">STARVATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The hypoxic ventilatory response falls approximately 40 percent among normal volunteers following 10 days of 500 <span class=\"nowrap\">kcal/day</span> diet restriction [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/39\" class=\"abstract_t\">39</a>]. There is little change in the hypercapnic ventilatory response. Prolonged caloric restriction can have other effects on pulmonary function, including the development of hyperinflation combined with emphysematous radiographic changes [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/40\" class=\"abstract_t\">40</a>]. (See <a href=\"topic.htm?path=anorexia-nervosa-in-adults-and-adolescents-medical-complications-and-their-management#H1782633\" class=\"medical medical_review\">&quot;Anorexia nervosa in adults and adolescents: Medical complications and their management&quot;, section on 'Pulmonary'</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">NEUROMUSCULAR DISEASE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Impairment of the ventilatory response to CO<sub>2</sub> occurs in patients with a wide variety of neuromuscular diseases [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/41\" class=\"abstract_t\">41</a>]. The reduced ventilatory response is due to neuromuscular weakness, and ventilatory drive, as measured by mouth occlusion pressure, is usually well preserved [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/42-44\" class=\"abstract_t\">42-44</a>]. (See <a href=\"topic.htm?path=control-of-ventilation#H19\" class=\"medical medical_review\">&quot;Control of ventilation&quot;, section on 'Mouth occlusion pressure'</a>.)</p><p>Patients with neuromuscular disease show different first-breath ventilatory responses to graded elastic and resistive loads [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/45\" class=\"abstract_t\">45</a>]. These abnormalities in respiratory timing suggest that neuromuscular diseases impair respiratory perception as well as respiratory muscle strength. (See <a href=\"topic.htm?path=respiratory-muscle-weakness-due-to-neuromuscular-disease-clinical-manifestations-and-evaluation\" class=\"medical medical_review\">&quot;Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">DRUGS AFFECTING VENTILATORY DRIVE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A variety of drugs can affect central ventilatory drive. These medications may either depress or stimulate ventilation, and may be useful therapeutically in some clinical situations.</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Central nervous system depressants</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several classes of drugs suppress central respiratory drive, including opiates, barbiturates, and benzodiazepines. These medications should be used judiciously in patients with preexisting hypoventilation, but may be useful in patients with hyperventilation secondary to pain, anxiety, or malignant pleural effusion [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/46\" class=\"abstract_t\">46</a>]. (See <a href=\"topic.htm?path=pain-control-in-the-critically-ill-adult-patient\" class=\"medical medical_review\">&quot;Pain control in the critically ill adult patient&quot;</a> and <a href=\"topic.htm?path=sedative-analgesic-medications-in-critically-ill-adults-selection-initiation-maintenance-and-withdrawal\" class=\"medical medical_review\">&quot;Sedative-analgesic medications in critically ill adults: Selection, initiation, maintenance, and withdrawal&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Medroxyprogesterone</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Medroxyprogesterone increases the ventilatory drive in normal males, leading to about a 5 mmHg (0.67 kPa) fall in arterial tension of carbon dioxide (PaCO<sub>2</sub>) [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/47\" class=\"abstract_t\">47</a>]. The drug has been used to treat patients with excessive polycythemia of high altitude and central hypoventilation syndromes, such as the obesity-hypoventilation syndrome [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/48-50\" class=\"abstract_t\">48-50</a>]. (See <a href=\"topic.htm?path=treatment-and-prognosis-of-the-obesity-hypoventilation-syndrome\" class=\"medical medical_review\">&quot;Treatment and prognosis of the obesity hypoventilation syndrome&quot;</a>.)</p><p>Its effectiveness in treating hypercapnia associated with COPD is unclear; reductions in PaCO<sub>2</sub> are not generally accompanied by improvements in other objective or subjective outcome measures. As an example, one trial of medroxyprogesterone in seven patients with hypercapnic chronic bronchitis found that treatment lowered the mean PaCO<sub>2</sub> from 51 to 44 mmHg (6.78 to 5.85 kPa), but had no effect upon sensations of dyspnea or 12-minute walking distance [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/51\" class=\"abstract_t\">51</a>].</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h2\">Theophylline</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=theophylline-drug-information\" class=\"drug drug_general\">Theophylline</a> increases the hypoxic ventilatory response and prevents the fall in hypoxic ventilatory response that normally occurs after 15 minutes of hypoxemia [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/52\" class=\"abstract_t\">52</a>]. Like medroxyprogesterone, theophylline may have some utility in the treatment of central hypoventilatory states, but its utility in hypercapnia secondary to obstructive sleep apnea is limited.</p><p>In a case report, <a href=\"topic.htm?path=theophylline-drug-information\" class=\"drug drug_general\">theophylline</a> was used successfully to treat a woman with diabetes mellitus, neuropathy, and end stage renal disease who had multiple cardiorespiratory arrests secondary to severe Cheyne-Stokes respiration [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/53\" class=\"abstract_t\">53</a>].</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h2\">Acetazolamide</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=acetazolamide-drug-information\" class=\"drug drug_general\">Acetazolamide</a>, an inhibitor of carbonic anhydrase, has several effects relevant to ventilation.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the brain, by blocking CO<sub>2</sub> conversion to bicarbonate in tissue capillaries, <a href=\"topic.htm?path=acetazolamide-drug-information\" class=\"drug drug_general\">acetazolamide</a> can acutely raise local tissue partial pressure of carbon dioxide (PCO<sub>2</sub>). Acetazolamide also lowers cerebrospinal fluid bicarbonate in normal individuals at both 3000 and 14,000 feet [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/54\" class=\"abstract_t\">54</a>]. Locally elevated PCO<sub>2</sub> and lower pH in the brain would increase central ventilatory drive and lower PaCO<sub>2</sub>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the kidney, <a href=\"topic.htm?path=acetazolamide-drug-information\" class=\"drug drug_general\">acetazolamide</a> increases retention of hydrogen ion and increases renal excretion of bicarbonate, causing a metabolic acidosis over several hours; the metabolic acidosis further increases respiratory drive.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Opposing the effects that promote increased ventilation, <a href=\"topic.htm?path=acetazolamide-drug-information\" class=\"drug drug_general\">acetazolamide</a> blocks the reciprocal conversion of bicarbonate to CO<sub>2</sub> in pulmonary capillaries, thereby impairing the lung's ability to excrete CO<sub>2</sub>. This could lead to an increase in PaCO<sub>2</sub> if ventilation remained constant. However, in normal individuals acetazolamide leads to increased minute ventilation resulting in lower end-tidal PCO<sub>2</sub>, lower PaCO<sub>2</sub>, and higher arterial oxygen tension (PaO<sub>2</sub>) [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/54,55\" class=\"abstract_t\">54,55</a>].</p><p/><p>Patients receiving <a href=\"topic.htm?path=acetazolamide-drug-information\" class=\"drug drug_general\">acetazolamide</a> who are able to increase their ventilation will decrease their PaCO<sub>2</sub> because their increased ventilatory drive will surpass their impaired lung excretion of CO<sub>2</sub>. In contrast, patients who are unable to augment their ventilation (eg, those with severe COPD) may develop a severe respiratory acidosis on acetazolamide [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/56\" class=\"abstract_t\">56</a>]. A review of the use of acetazolamide in patients with COPD raises concerns of its use in those with severe COPD [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/57\" class=\"abstract_t\">57</a>].</p><p><a href=\"topic.htm?path=acetazolamide-drug-information\" class=\"drug drug_general\">Acetazolamide</a> is effective in the prophylaxis and treatment of acute and chronic mountain sickness [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/58-60\" class=\"abstract_t\">58-60</a>]. This effect is likely due to increased ventilation and decreased oxygen desaturation with acetazolamide. (See <a href=\"topic.htm?path=high-altitude-illness-physiology-risk-factors-and-general-prevention\" class=\"medical medical_review\">&quot;High altitude illness: Physiology, risk factors, and general prevention&quot;</a>.)</p><p>In addition, <a href=\"topic.htm?path=acetazolamide-drug-information\" class=\"drug drug_general\">acetazolamide</a> reduces central sleep apneas in patients with heart failure and Cheyne-Stokes respiration, although not without adverse effects. A beneficial effect was shown in a small cross-over study of 12 patients with heart failure who had a reduction in episodes of central sleep apnea when acetazolamide was given an hour before bedtime [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/61\" class=\"abstract_t\">61</a>]. Another study found that four days of acetazolamide led to reduced Cheyne-Stokes respiration and a blunted hypoxic ventilatory response, while it increased hypercapnic ventilatory response and lowered the achievable work load [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/62\" class=\"abstract_t\">62</a>]. The efficacy and side effects of long term treatment are unknown.</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h2\">Antioxidants</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A combination of antioxidants &ndash; vitamins E, A, and C for two months, <a href=\"topic.htm?path=allopurinol-drug-information\" class=\"drug drug_general\">allopurinol</a> for 15 days, and N-acetylcysteine for three days &ndash; increases the sensitivity of the ventilatory response to CO<sub>2</sub> in normal subjects during hyperoxic unloaded breathing and after resistive breathing [<a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/63\" class=\"abstract_t\">63</a>]. The effect of antioxidants on ventilatory response to CO<sub>2</sub> in non-hyperoxic conditions or in patients with lung disease is unknown.</p><p class=\"headingAnchor\" id=\"H5550924\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A variety of disorders, including chronic obstructive pulmonary disease, asthma, Ondine's curse, carotid body resection, Cheyne-Stokes respiration, myxedema, starvation, and neuromuscular disease, are associated with abnormal ventilatory control. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Some patients with chronic obstructive pulmonary disease (COPD) develop hypercapnia (ie, elevated arterial carbon dioxide tension [PaCO<sub>2</sub>] or CO<sub>2</sub> retention) and hypoxemia. The development of hypercapnia in COPD usually occurs in patients with more severe COPD who also have blunted hypoxic and hypercapnic respiratory drives. Some hypercapnic, hypoxemic patients with COPD develop increased CO<sub>2</sub> retention when O<sub>2</sub> is administered. (See <a href=\"#H2\" class=\"local\">'Chronic obstructive pulmonary disease'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Some patients with asthma demonstrate depressed hypoxic and hypercapnic ventilatory responses as well as a reduced perception of dyspnea. These patients appear to be at an increased risk of near fatal asthma exacerbations, characterized by severe hypoxemia and hypercapnia. It is thought that the reduced perception of dyspnea contributes to delays in seeking medical attention during asthma exacerbations. (See <a href=\"#H3\" class=\"local\">'Asthma'</a> above and <a href=\"topic.htm?path=identifying-patients-at-risk-for-fatal-asthma#H10\" class=\"medical medical_review\">&quot;Identifying patients at risk for fatal asthma&quot;, section on 'Poor perception of dyspnea'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The term Ondine's curse has been applied to patients with alveolar hypoventilation due to impaired autonomic control of ventilation, but normal voluntary control. The most common cause is congenital central hypoventilation; other etiologies include brainstem injury or tumor and late-onset central hypoventilation syndrome. (See <a href=\"#H4\" class=\"local\">'Ondine's curse'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Congenital central hypoventilation syndrome (CCHS) is associated with a nearly absent respiratory response to hypoxia and hypercapnia, no respiratory discomfort during CO<sub>2</sub> inhalation, mildly elevated PaCO<sub>2</sub> during wakefulness, and markedly elevated PaCO<sub>2</sub> during non-REM sleep. CCHS can occur in association with Hirschsprung's disease, a condition characterized by abnormalities of the cholinergic innervation of the gastrointestinal tract. (See <a href=\"#H5\" class=\"local\">'Congenital central hypoventilation syndrome'</a> above and <a href=\"topic.htm?path=congenital-central-hypoventilation-syndrome-and-other-causes-of-sleep-related-hypoventilation-in-children#H267786\" class=\"medical medical_review\">&quot;Congenital central hypoventilation syndrome and other causes of sleep-related hypoventilation in children&quot;, section on 'Congenital central hypoventilation syndrome'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cheyne-Stokes respiration (CSR) describes cyclic breathing in which apnea is followed by gradually increasing respiratory frequency and tidal volume (ie, hyperpnea), then gradually decreasing respiratory frequency and tidal volume until the next apneic period. The diagnosis and management of CSR are discussed separately. (See <a href=\"#H8\" class=\"local\">'Cheyne-stokes respiration'</a> above and <a href=\"topic.htm?path=sleep-disordered-breathing-in-heart-failure\" class=\"medical medical_review\">&quot;Sleep-disordered breathing in heart failure&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A wide variety of neuromuscular diseases are associated with impairment of the ventilatory response to CO<sub>2</sub>. The reduced ventilatory response is usually due to neuromuscular weakness; ventilatory drive is usually well-preserved. (See <a href=\"#H14\" class=\"local\">'Neuromuscular disease'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rare causes of hypoventilation include carotid body resection or injury, myxedema, and starvation. (See <a href=\"#H7\" class=\"local\">'Carotid body resection'</a> above and <a href=\"#H12\" class=\"local\">'Myxedema'</a> above and <a href=\"#H13\" class=\"local\">'Starvation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A variety of drugs can affect central ventilatory drive; central nervous system depressants can decrease ventilatory drive, while medroxyprogesterone, <a href=\"topic.htm?path=theophylline-drug-information\" class=\"drug drug_general\">theophylline</a>, <a href=\"topic.htm?path=acetazolamide-drug-information\" class=\"drug drug_general\">acetazolamide</a>, and antioxidants can modestly increase ventilatory drive. However, the clinical use of these drugs to adjust ventilatory drive is limited. (See <a href=\"#H15\" class=\"local\">'Drugs affecting ventilatory drive'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/1\" class=\"nounderline abstract_t\">Louren&ccedil;o RV, Miranda JM. Drive and performance of the ventilatory apparatus in chronic obstructive lung disease. N Engl J Med 1968; 279:53.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/2\" class=\"nounderline abstract_t\">Matthews AW, Howell JB. Assessment of responsiveness to carbon dioxide in patients with chronic airways obstruction by rate of isometric inspiratory pressure development. Clin Sci Mol Med 1976; 50:199.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/3\" class=\"nounderline abstract_t\">Javaheri S, Blum J, Kazemi H. Pattern of breathing and carbon dioxide retention in chronic obstructive lung disease. Am J Med 1981; 71:228.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/4\" class=\"nounderline abstract_t\">Bradley CA, Fleetham JA, Anthonisen NR. Ventilatory control in patients with hypoxemia due to obstructive lung disease. Am Rev Respir Dis 1979; 120:21.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/5\" class=\"nounderline abstract_t\">Lee J, Read J. Effect of oxygen breathing on distribution of pulmonary blood flow in chronic obstructive lung disease. Am Rev Respir Dis 1967; 96:1173.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/6\" class=\"nounderline abstract_t\">Lenfant C. Arterial-alveolar difference in PCO2 during air and oxygen breathing. J Appl Physiol 1966; 21:1356.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/7\" class=\"nounderline abstract_t\">Kikuchi Y, Okabe S, Tamura G, et al. Chemosensitivity and perception of dyspnea in patients with a history of near-fatal asthma. N Engl J Med 1994; 330:1329.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/8\" class=\"nounderline abstract_t\">Rebuck AS, Read J. Patterns of ventilatory response to carbon dioxide during recovery from severe asthma. Clin Sci 1971; 41:13.</a></li><li class=\"breakAll\">Kazemi H, Kanarek DJ. Gas exchange in asthma. In: Status Asthmaticus, Weiss EB (Ed), United Park Press, Baltimore 1978. p.101.</li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/10\" class=\"nounderline abstract_t\">Severinghaus, JW, Mitchell, RA. Ondine's curse - failure of respiratory center automaticity while awake. Clin Res 1962; 10:122.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/11\" class=\"nounderline abstract_t\">Mellins RB, Balfour HH Jr, Turino GM, Winters RW. Failure of automatic control of ventilation (Ondine's curse). Report of an infant born with this syndrome and review of the literature. Medicine (Baltimore) 1970; 49:487.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/12\" class=\"nounderline abstract_t\">Mullan S, Hosobuchi Y. Respiratory hazards of high cervical percutaneous cordotomy. J Neurosurg 1968; 28:291.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/13\" class=\"nounderline abstract_t\">Marin-Sanabria EA, Kobayashi N, Miyake S, Kohmura E. Snoring associated with Ondine's curse in a patient with brainstem glioma. J Clin Neurosci 2006; 13:370.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/14\" class=\"nounderline abstract_t\">Lassman AB, Mayer SA. Paroxysmal apnea and vasomotor instability following medullary infarction. Arch Neurol 2005; 62:1286.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/15\" class=\"nounderline abstract_t\">Bogousslavsky J, Khurana R, Deruaz JP, et al. Respiratory failure and unilateral caudal brainstem infarction. Ann Neurol 1990; 28:668.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/16\" class=\"nounderline abstract_t\">Trang H, Dehan M, Beaufils F, et al. The French Congenital Central Hypoventilation Syndrome Registry: general data, phenotype, and genotype. Chest 2005; 127:72.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/17\" class=\"nounderline abstract_t\">Idiopathic congenital central hypoventilation syndrome: diagnosis and management. American Thoracic Society. Am J Respir Crit Care Med 1999; 160:368.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/18\" class=\"nounderline abstract_t\">Paton JY, Swaminathan S, Sargent CW, Keens TG. Hypoxic and hypercapnic ventilatory responses in awake children with congenital central hypoventilation syndrome. Am Rev Respir Dis 1989; 140:368.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/19\" class=\"nounderline abstract_t\">Shannon DC, Marsland DW, Gould JB, et al. Central hypoventilation during quiet sleep in two infants. Pediatrics 1976; 57:342.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/20\" class=\"nounderline abstract_t\">Shea SA, Andres LP, Shannon DC, et al. Respiratory sensations in subjects who lack a ventilatory response to CO2. Respir Physiol 1993; 93:203.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/21\" class=\"nounderline abstract_t\">Shea SA, Andres LP, Shannon DC, Banzett RB. Ventilatory responses to exercise in humans lacking ventilatory chemosensitivity. J Physiol 1993; 468:623.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/22\" class=\"nounderline abstract_t\">Gozal D, Marcus CL, Ward SL, Keens TG. Ventilatory responses to passive leg motion in children with congenital central hypoventilation syndrome. Am J Respir Crit Care Med 1996; 153:761.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/23\" class=\"nounderline abstract_t\">Shea SA. Life without ventilatory chemosensitivity. Respir Physiol 1997; 110:199.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/24\" class=\"nounderline abstract_t\">Gozal D, Simakajornboon N. Passive motion of the extremities modifies alveolar ventilation during sleep in patients with congenital central hypoventilation syndrome. Am J Respir Crit Care Med 2000; 162:1747.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/25\" class=\"nounderline abstract_t\">Ize-Ludlow D, Gray JA, Sperling MA, et al. Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation presenting in childhood. Pediatrics 2007; 120:e179.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/26\" class=\"nounderline abstract_t\">Katz ES, McGrath S, Marcus CL. Late-onset central hypoventilation with hypothalamic dysfunction: a distinct clinical syndrome. Pediatr Pulmonol 2000; 29:62.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/27\" class=\"nounderline abstract_t\">Carroll MS, Patwari PP, Weese-Mayer DE. Carbon dioxide chemoreception and hypoventilation syndromes with autonomic dysregulation. J Appl Physiol (1985) 2010; 108:979.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/28\" class=\"nounderline abstract_t\">Winter, B. Surgical treatment of asthma, chronic bronchitis and emphysema by bilateral carotid body resection. Respir Ther 1975; 5:18.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/29\" class=\"nounderline abstract_t\">Stulbarg MS, Winn WR, Kellett LE. Bilateral carotid body resection for the relief of dyspnea in severe chronic obstructive pulmonary disease. Physiologic and clinical observations in three patients. Chest 1989; 95:1123.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/30\" class=\"nounderline abstract_t\">Lugliani R, Whipp BJ, Seard C, Wasserman K. Effect of bilateral carotid-body resection on ventilatory control at rest and during exercise in man. N Engl J Med 1971; 285:1105.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/31\" class=\"nounderline abstract_t\">Cherniack NS, Longobardo GS. Cheyne-Stokes breathing. An instability in physiologic control. N Engl J Med 1973; 288:952.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/32\" class=\"nounderline abstract_t\">Dowell AR, Buckley CE 3rd, Cohen R, et al. Cheyne-Stokes respiration. A review of clinical manifestations and critique of physiological mechanisms. Arch Intern Med 1971; 127:712.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/33\" class=\"nounderline abstract_t\">Brown, HW, Plum, F. The neurologic basis of Cheyne-Stokes respiration. Am J Med 1961; 30:849.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/34\" class=\"nounderline abstract_t\">Javaheri S. A mechanism of central sleep apnea in patients with heart failure. N Engl J Med 1999; 341:949.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/35\" class=\"nounderline abstract_t\">Javaheri S, Parker TJ, Wexler L, et al. Occult sleep-disordered breathing in stable congestive heart failure. Ann Intern Med 1995; 122:487.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/36\" class=\"nounderline abstract_t\">Zwillich CW, Pierson DJ, Hofeldt FD, et al. Ventilatory control in myxedema and hypothyroidism. N Engl J Med 1975; 292:662.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/37\" class=\"nounderline abstract_t\">NORDQVIST P, DHUNER KG, STENBERG K, ORNDAHL G. Myxoedema coma and carbon dioxide-retention. Acta Med Scand 1960; 166:189.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/38\" class=\"nounderline abstract_t\">MASSUMI RA, WINNACKER JL. SEVERE DEPRESSION OF THE RESPIRATORY CENTER IN MYXEDEMA. Am J Med 1964; 36:876.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/39\" class=\"nounderline abstract_t\">Doekel RC Jr, Zwillich CW, Scoggin CH, et al. Clinical semi-starvation: depression of hypoxic ventilatory response. N Engl J Med 1976; 295:358.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/40\" class=\"nounderline abstract_t\">Coxson HO, Chan IH, Mayo JR, et al. Early emphysema in patients with anorexia nervosa. Am J Respir Crit Care Med 2004; 170:748.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/41\" class=\"nounderline abstract_t\">Johnson DC, Kazemi H. Central control of ventilation in neuromuscular disease. Clin Chest Med 1994; 15:607.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/42\" class=\"nounderline abstract_t\">B&eacute;gin R, Bureau MA, Lupien L, Lemieux B. Control and modulation of respiration in Steinert's myotonic dystrophy. Am Rev Respir Dis 1980; 121:281.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/43\" class=\"nounderline abstract_t\">B&eacute;gin R, Bureau MA, Lupien L, Lemieux B. Control of breathing in Duchenne's muscular dystrophy. Am J Med 1980; 69:227.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/44\" class=\"nounderline abstract_t\">Skatrud J, Iber C, McHugh W, et al. Determinants of hypoventilation during wakefulness and sleep in diaphragmatic paralysis. Am Rev Respir Dis 1980; 121:587.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/45\" class=\"nounderline abstract_t\">Axen K, Bishop M, Haas F. Respiratory load compensation in neuromuscular disorders. J Appl Physiol (1985) 1988; 64:2659.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/46\" class=\"nounderline abstract_t\">Liistro G, Aubert G, Rodenstein DO. Management of sleep apnoea syndrome. Eur Respir J 1995; 8:1751.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/47\" class=\"nounderline abstract_t\">Skatrud JB, Dempsey JA, Kaiser DG. Ventilatory response to medroxyprogesterone acetate in normal subjects: time course and mechanism. J Appl Physiol Respir Environ Exerc Physiol 1978; 44:939.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/48\" class=\"nounderline abstract_t\">Kryger M, McCullough RE, Collins D, et al. Treatment of excessive polycythemia of high altitude with respiratory stimulant drugs. Am Rev Respir Dis 1978; 117:455.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/49\" class=\"nounderline abstract_t\">Sutton FD Jr, Zwillich CW, Creagh CE, et al. Progesterone for outpatient treatment of Pickwickian syndrome. Ann Intern Med 1975; 83:476.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/50\" class=\"nounderline abstract_t\">Lyons HA, Huang CT. Therapeutic use of progesterone in alveolar hypoventilation associated with obesity. Am J Med 1968; 44:881.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/51\" class=\"nounderline abstract_t\">Al-Damluji S. The effect of ventilatory stimulation with medroxyprogesterone on exercise performance and the sensation of dyspnoea in hypercapnic chronic bronchitis. Br J Dis Chest 1986; 80:273.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/52\" class=\"nounderline abstract_t\">Igarashi T, Nishimura M, Kobayashi S, et al. Dependency on the rate of change in PaO2 of the ventilatory response to progressive hypoxia. Am J Respir Crit Care Med 1995; 151:1815.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/53\" class=\"nounderline abstract_t\">Pesek CA, Cooley R, Narkiewicz K, et al. Theophylline therapy for near-fatal Cheyne-Stokes respiration. A case report. Ann Intern Med 1999; 130:427.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/54\" class=\"nounderline abstract_t\">Kronenberg RS, Cain SM. Effects of acetazolamide and hypoxia on cerebrospinal fluid bicarbonate. J Appl Physiol 1968; 24:17.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/55\" class=\"nounderline abstract_t\">Swenson ER, Hughes JM. Effects of acute and chronic acetazolamide on resting ventilation and ventilatory responses in men. J Appl Physiol (1985) 1993; 74:230.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/56\" class=\"nounderline abstract_t\">Skatrud JB, Dempsey JA. Relative effectiveness of acetazolamide versus medroxyprogesterone acetate in correction of chronic carbon dioxide retention. Am Rev Respir Dis 1983; 127:405.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/57\" class=\"nounderline abstract_t\">Adamson R, Swenson ER. Acetazolamide Use in Severe Chronic Obstructive Pulmonary Disease. Pros and Cons. Ann Am Thorac Soc 2017; 14:1086.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/58\" class=\"nounderline abstract_t\">Forwand SA, Landowne M, Follansbee JN, Hansen JE. Effect of acetazolamide on acute mountain sickness. N Engl J Med 1968; 279:839.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/59\" class=\"nounderline abstract_t\">Grissom CK, Roach RC, Sarnquist FH, Hackett PH. Acetazolamide in the treatment of acute mountain sickness: clinical efficacy and effect on gas exchange. Ann Intern Med 1992; 116:461.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/60\" class=\"nounderline abstract_t\">Richalet JP, Rivera M, Bouchet P, et al. Acetazolamide: a treatment for chronic mountain sickness. Am J Respir Crit Care Med 2005; 172:1427.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/61\" class=\"nounderline abstract_t\">Javaheri S. Acetazolamide improves central sleep apnea in heart failure: a double-blind, prospective study. Am J Respir Crit Care Med 2006; 173:234.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/62\" class=\"nounderline abstract_t\">Fontana M, Emdin M, Giannoni A, et al. Effect of acetazolamide on chemosensitivity, Cheyne-Stokes respiration, and response to effort in patients with heart failure. Am J Cardiol 2011; 107:1675.</a></li><li><a href=\"https://www.uptodate.com/contents/disorders-of-ventilatory-control/abstract/63\" class=\"nounderline abstract_t\">Zakynthinos S, Katsaounou P, Karatza MH, et al. Antioxidants increase the ventilatory response to hyperoxic hypercapnia. Am J Respir Crit Care Med 2007; 175:62.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5113 Version 19.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H5550924\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">CHRONIC OBSTRUCTIVE PULMONARY DISEASE</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">ASTHMA</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">ONDINE'S CURSE</a><ul><li><a href=\"#H5\" id=\"outline-link-H5\">Congenital central hypoventilation syndrome</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Late-onset central hypoventilation syndrome</a></li><li><a href=\"#H21873808\" id=\"outline-link-H21873808\">Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD)</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">CAROTID BODY RESECTION</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">CHEYNE-STOKES RESPIRATION</a><ul><li><a href=\"#H9\" id=\"outline-link-H9\">Mechanism</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Comorbidities</a></li><li><a href=\"#H5551029\" id=\"outline-link-H5551029\">Diagnosis</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Management</a></li></ul></li><li><a href=\"#H12\" id=\"outline-link-H12\">MYXEDEMA</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">STARVATION</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">NEUROMUSCULAR DISEASE</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">DRUGS AFFECTING VENTILATORY DRIVE</a><ul><li><a href=\"#H16\" id=\"outline-link-H16\">Central nervous system depressants</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">Medroxyprogesterone</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">Theophylline</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">Acetazolamide</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">Antioxidants</a></li></ul></li><li><a href=\"#H5550924\" id=\"outline-link-H5550924\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PULM/5113|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/61737\" class=\"graphic graphic_figure\">- Ventilatory response in asthma</a></li><li><a href=\"image.htm?imageKey=PULM/62712\" class=\"graphic graphic_figure\">- Dyspnea in asthmatics</a></li></ul></li><li><div id=\"PULM/5113|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/88393\" class=\"graphic graphic_table\">- ROHHADNET syndrome</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=anorexia-nervosa-in-adults-and-adolescents-medical-complications-and-their-management\" class=\"medical medical_review\">Anorexia nervosa in adults and adolescents: Medical complications and their management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=central-sleep-apnea-risk-factors-clinical-presentation-and-diagnosis\" class=\"medical medical_review\">Central sleep apnea: Risk factors, clinical presentation, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=congenital-central-hypoventilation-syndrome-and-other-causes-of-sleep-related-hypoventilation-in-children\" class=\"medical medical_review\">Congenital central hypoventilation syndrome and other causes of sleep-related hypoventilation in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=control-of-ventilation\" class=\"medical medical_review\">Control of ventilation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=high-altitude-illness-physiology-risk-factors-and-general-prevention\" class=\"medical medical_review\">High altitude illness: Physiology, risk factors, and general prevention</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=identifying-patients-at-risk-for-fatal-asthma\" class=\"medical medical_review\">Identifying patients at risk for fatal asthma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=myxedema-coma\" class=\"medical medical_review\">Myxedema coma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pain-control-in-the-critically-ill-adult-patient\" class=\"medical medical_review\">Pain control in the critically ill adult patient</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=respiratory-function-in-thyroid-disease\" class=\"medical medical_review\">Respiratory function in thyroid disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=respiratory-muscle-weakness-due-to-neuromuscular-disease-clinical-manifestations-and-evaluation\" class=\"medical medical_review\">Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sedative-analgesic-medications-in-critically-ill-adults-selection-initiation-maintenance-and-withdrawal\" class=\"medical medical_review\">Sedative-analgesic medications in critically ill adults: Selection, initiation, maintenance, and withdrawal</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sleep-disordered-breathing-in-heart-failure\" class=\"medical medical_review\">Sleep-disordered breathing in heart failure</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=stroke-related-pulmonary-complications-and-abnormal-respiratory-patterns\" class=\"medical medical_review\">Stroke-related pulmonary complications and abnormal respiratory patterns</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-evaluation-diagnosis-and-treatment-of-the-adult-patient-with-acute-hypercapnic-respiratory-failure\" class=\"medical medical_review\">The evaluation, diagnosis, and treatment of the adult patient with acute hypercapnic respiratory failure</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prognosis-of-the-obesity-hypoventilation-syndrome\" class=\"medical medical_review\">Treatment and prognosis of the obesity hypoventilation syndrome</a></li></ul></div></div>","javascript":null}